



Scientific Abstracts

Publication Only

Sjögren's syndrome

ABS0762 FREQUENCY, CHARACTERISTICS AND PREDICTORS OF CENTRAL AND PERIPHERAL NEUROLOGICAL INVOLVEMENT IN SJÖGREN'S DISEASE: DATA FROM PORTRESS, THE PORTUGUESE REGISTRY OF SJÖGREN'S DISEASE

R. Pereira da Costa^{1 2}, M. Bandeira^{1 2}, M. Silvério-António^{1 2}, A.R. Lopes^{1 2}, F. Cunha Santos³, P. Pereira⁴, D.B. Raimundo⁵, A. Cunha⁶, C. Pinto Oliveira⁷, A.C. Duarte⁸, J. Madruga Dias⁹, M.E. Santos¹⁰, M.J. Gonçalves^{10 11 12}, A.C. Moniz¹⁰, A. Maduro¹³, M. Luis¹³, A. Valido¹⁴, M. Oliveira¹⁵, L. Brites¹⁶, C. Tenazinha¹⁷...V.C. Romão²

[Show more](#) ▾[Share](#) [Cite](#)<https://doi.org/10.1016/j.ard.2025.06.1694> ↗[Get rights and content](#) ↗

Abstract

Background:

Sjogren's disease (SjD) systemic affection is being increasingly recognized. Prevalence of peripheral (PNS) and central (CNS) nervous system involvement in SjD and risk factors for these manifestations have not been clearly established.

Objectives:

To define the clinical characteristics of SjD patients with CNS and/or PNS involvement and to find predictors of this involvement.

Methods:

We included patients from the Portuguese registry of SjD (PORTRESS) who had information regarding presence or absence of PNS and/or CNS involvement. Demographic, clinical and treatment data were collected. Variables were compared according to parametric or non-parametric tests, as applicable. Predictors of neurological (PNS and/or CNS), PNS (vs. no PNS) and CNS (vs. no CNS) involvement were identified through binomial logistic regression modelling.

Results:

We included 1233 patients, 94.2% female, with a mean age of 61.8 ± 14.3 years and a median disease duration of 11.0 [IQR 11.2] years (Table 1). 65 patients (5.3%) had a history of neurological involvement, 48 (3.9%) with PNS and 20 (1.6%) with CNS affection (Figure 1). Sensorimotor polyneuropathy (20.8%) and sensory polyneuropathy (20.8%) were the most common subtypes of PNS affection. Aseptic meningitis (25.0%) was the most common CNS manifestation. Patients with neurological involvement were more commonly male and had more active disease, translated by higher ESSDAI scores, markers of B cell activity (cryoglobulinemia, low C4, monoclonal gammopathy), and skin, glandular and respiratory involvements (according to ESSDAI definition). On multivariate analysis, male sex (OR 2.77 [1.22-6.31], $p=0.015$), purpura (OR 2.72 [1.20-6.19], $p=0.017$), monoclonal gammopathy (OR 2.49 [1.00-6.17], $p=0.049$) and a higher non-neurological baseline ESSDAI (OR 1.08 [1.02-1.15], $p=0.011$) were associated with neurological involvement. PNS involvement was associated with older age at symptom onset (OR 1.03 [1.01-1.06], $p=0.008$), low C4 (OR 3.08 [1.25-7.59], $p=0.015$), persistent salivary gland swelling (OR 3.98 [1.63-9.76], $p=0.003$), purpura/cutaneous vasculitis (OR 2.98 [1.10-8.03], $p=0.031$) and CNS affection (OR 7.32 [1.78-30.16], $p=0.006$). In turn, CNS disease was only associated with PNS involvement (OR 5.29 [1.10-25.35], $p=0.037$).

Conclusion:

In the Portuguese cohort of SjD, 5.3% of patients had confirmed neurological involvement. Predictors of these manifestations included male sex, purpura, monoclonal gammopathy and a higher non-neurological baseline ESSDAI. Moreover, a bidirectional association was observed between CNS and PNS affection. In addition, PNS disease was specifically associated with purpura, older age at SjD symptom onset, low C4 and persistent salivary gland swelling.

Table 1 – Demographic and clinical characteristics of SjD patients with and without PNS and/or CNS involvement.

	SjD patients with PNS and/or CNS involvement N=65*	SjD patients without PNS or CNS involvement N=1168**	p
Female	57 (87.7)	110 (96.5)	0.029
Caucasian / White	52 (92.9)	915 (92.9)	1.000
Age at diagnosis	52.7[15.2]	52.8[14.5]	0.960
ACR/EULAR 2016	41 (64.1)	676 (60.0)	0.517
ANA	57 (90.5)	957 (90.6)	0.969
anti-Ro	51 (81.0)	920 (80.6)	0.939
anti-La	23 (38.3)	489 (44.6)	0.343
Rheumatoid factor	27 (48.1)	485 (48.2)	0.899
Cryoglobulin	10 (27.8)	52 (14.2)	0.031
Low C3	12 (20.0)	177 (17.5)	0.615
Low C4	10 (16.7)	88 (8.7)	0.037
Persistent salivary gland swelling	9 (14.8)	75 (7.2)	0.043
Purpura / cutaneous vasculitis	10 (16.7)	57 (5.5)	0.002
Lymphopenia	16 (25.4)	205 (19.9)	0.288
Monoclonal gammopathy	8 (13.6)	52 (5.3)	0.016
Focus score ≥ 1	25 (52.1)	405 (48.5)	0.629
Baseline ESSDAI	4.5 [11.5]	2.0 [4.0]	<0.001
Baseline ESSDAI without neurological domains	3.0 [7.0]	2.0 [4.0]	0.005
Baseline ESSPRI	6.0 [5.3]	5.3 [4.66]	0.324

Results presented as mean±standard deviation or median [interquartile range] or n (%).

* Caucasian / white: N=56, age at diagnosis: N=61, ACR/EULAR 2016: N=64, ANA: N=63, anti-Ro: N=63, anti-La: N=60, Rheumatoid factor: N=55, Cryoglobulin: N=36, Low C3: N=60, Low C4: N=60, Persistent salivary gland swelling: N=61, Purpura / cutaneous vasculitis: N=60, Lymphopenia: N=63, Monoclonal gammopathy: N=59, Focus score ≥ 1 : N=48, Baseline ESSDAI: N=58, Baseline ESSDAI without neurological domains: N=58, Baseline ESSPRI: N=41

** Caucasian / white: N=965, age at diagnosis: N=1060, ACR/EULAR 2016: N=1127, ANA: N=1056, anti-Ro: N=1142, anti-La: N=1097, Rheumatoid factor: N=1006, Cryoglobulin: N=367, Low C3: N=1014, Low C4: N=1014, Persistent salivary gland swelling: N=1040, Purpura / cutaneous vasculitis: N=1034, Lymphopenia: N=1032, Monoclonal gammopathy: N=988, Focus score ≥ 1 : N=835, Baseline ESSDAI: N=927, Baseline ESSDAI without neurological domains: N=827, Baseline ESSPRI: N=541

[Download: Download high-res image \(653KB\)](#)

[Download: Download full-size image](#)




Figure 1 - Frequency distribution of the types of manifestations of the peripheral (A) and central (B) nervous systems.

[Download: Download high-res image \(153KB\)](#)

[Download: Download full-size image](#)

REFERENCES:

NIL.

Acknowledgements:

PORTRESS Reuma.pt Task Force: Margarida Silva, Sara Paiva Dinis, Filipe Vinagre, Maria Helena Lourenço, Ana Bento Silva, Alexandra Daniel, Paula Valente, Inês Almeida, Maria Pontes Ferreira, Joana Silva-Dinis, Carlos Costa, Lúcia Teixeira, Filipe Araújo, Carlos Marques Gomes, Patrícia Pinto, Filipa Farinha, Teresa Nóvoa, Ana Rodrigues, Sara Cortes.

Disclosure of interests:

Roberto Pereira da Costa SPCare, Matilde Bandeira: None declared., Manuel Silvério-António: None declared, Ana Rita Lopes: None declared, Filipe Cunha Santos: None declared, Paulo Pereira: None declared, Diana B Raimundo: None declared, Anita Cunha: None declared, Cláudia Pinto Oliveira: None declared, Ana Catarina Duarte: None declared, João Madruga Dias: None declared, Mariana Emília Santos: None declared, Maria João Gonçalves: None declared, Ana Catarina Moniz: None declared, Ana Maduro: None declared, Mariana Luis: None declared, Ana Valido: None declared, Margarida Oliveira: None declared, Luísa Brites: None declared, Catarina Tenazinha: None declared, Nikita Khmelinskii: None declared, Filipe Barcelos: None declared, Joao Eurico Fonseca: None declared, Vasco C Romão SPCare, SPCare.

© The Authors 2025. This abstract is an open access article published in *Annals of Rheumatic Diseases* under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

[Special issue articles](#)

References (0)

Cited by (0)

[View full text](#)

Copyright © 2025 © Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.



All content on this site: Copyright © 2025 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

